Abstract
• X-linked adrenoleukodystrophy ALDP ABCD1 t1:7
• Acyl-CoA oxidase deficiency ACOX1 ACOX1 t1:8
• D-bifunctional protein deficiency DBP HSD17B4 t1:9
• 2-MethylacylCoA racemase deficiency AMACR AMACR t1:10
• Sterol carrier protein X deficiency SCPx SCP2 t1:11 (3) Peroxisomal alpha-oxidation
• Refsum disease (phytanoyl-CoA hydroxylase deficiency) PHYH/PAHX PHYH/PAHX t1:12 (4) Glyoxylate detoxification
• Hyperoxaluria Type 1 AGT AGXT t1:13 (5) H 2 O 2 -metabolism Acatalasaemia CAT [89] CAT
In all patients with established RCDP type 2 the activity of 171 DHAPAT is severely deficient, which results in a virtually 172 complete inability to synthesize ether phospholipids, including 173 plasmalogens. This is reflected in deficient plasmalogen levels 174 in all tissues investigated including erythrocytes. Importantly, in 175 all patients studied thus far, erythrocyte plasmalogens levels are 176 clearly deficient, which implies that erythrocyte plasmalogens 177 analysis is a reliable initial biochemical test. Molecular studies 178 have led to the identification of different mutations in the gene 179 coding for DHAPAT [54] . In 1994, the first case of isolated alkyl-DHAP synthase 183 deficiency (RCDP type 3) was described in a patient showing 184 all the clinical characteristics of RCDP [91] . Also in this patient 185 erythrocyte plasmalogens levels were completely deficient 186 whereas plasma phytanic acid levels were normal. Subsequent 187 studies in fibroblasts revealed the complete deficiency of alkyl-188 DHAP synthase with normal values for DHAPAT and phytanic 189 acid alpha-oxidation and a normally processed peroxisomal 190 thiolase. In literature only a single patient has been described 191 since [10] 
X-linked adrenoleukodystrophy

357
The phenotype of X-linked adrenoleukodystrophy (X-ALD) 358 varies wildly with at least six phenotypic variants described.
359
The classification of X-ALD is somewhat arbitrary and based 
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365 ALD (CCALD) and adrenomyeloneuropathy (AMN). Onset of 366 CCALD is between 3 and 10 years of age with progressive 367 behavioral, cognitive and neurologic deterioration, often 368 leading to total disability within 3 years. The cerebral phenotype 369 is not only observed in childhood but may also present later in 370 life in adolescence (adolescence cerebral ALD; ACALD) or 371 adulthood (adult-cerebral ALD). There is a marked difference 372 between the cerebral phenotypes on the one hand, and AMN on 373 the other, since the cerebral phenotype shows an inflammatory 374 reaction in the cerebral white matter, which resembles, but can 375 be distinguished from what is observed in multiple sclerosis. In 376 contrast to CCALD, the inflammatory response is absent or 377 mild in AMN, which has a much later age of onset (28 + 9 378 years), and a much slower rate of progression. Finally, it is 379 important to mention that approximately 40 to 50% of women, 380 heterozygous for X-ALD, develop AMN-like symptoms in 381 middle age or later. Cerebral involvement and adrenocortical 382 insufficiency are rare, however. For more detailed information 383 the reader is referred to the paper by Gärtner and Berger 384 elsewhere in this issue. , and other cell types 388 (see [49] for review). Analysis of plasma VLCFAs has proven 389 to be a powerful diagnostic method with very few, if any, false 390 negatives. In 15 to 20% of obligate heterozygotes, however, test 391 results are falsely negative, which makes mutation analysis the 392 only reliable test for heterozygote identification. Other 393 peroxisomal metabolites are normal in plasma from X-ALD 394 patients (see Table 2 and Fig. 2a ). The accumulation of VLCFAs 395 is due to the impaired oxidation of VLCFAs in peroxisomes. 396 Indeed, the rate of C26:0 oxidation in X-ALD fibroblasts is 20 397 to 30% of control, compared with a virtually complete 398 deficiency in fibroblasts from Zellweger patients lacking 399 peroxisomes.
400
The X-ALD or ABCD1 gene was identified in 1993, using a 401 positional cloning strategy [ Oezen et al. [53] showed that mitochondria, at least those • X-Linked adrenoleukodystrophy ↑ N N N t2:6
• Acyl-CoA oxidase deficiency ↑ (1) N N N t2:7
• D-bifunctional protein deficiency ↑
↑* ↑* ↑
t2:8
• Sterol carrier protein X (SCPx) deficiency N ↑* ↑* ↑ t2:9
• 2-methylacylCoA racemase (AMACR) deficiency N ↑* ↑* ↑ Footnote: (1) = plasma VLCFA-levels may not be elevated in all acylCoA oxidase deficient patients (see Rosewich et al. [60] ;
(2) = plasma VLCFA levels may not always be elevated in all DBP-deficient patients (see Ferdinandusse et al. [19] ); * = plasma pristanic acid and phytanic acid are usually elevated but may be deceptively low to even normal as a consequence of the reduced dietary intake of pristanic acid and/or phytanic acid. N = normal. t2:10
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458 showing bilateral enhancing lesions in the centrum semiovale 459 and a generally hypodense cerebral white matter. A second 460 patient was described by Wanders et al. [92] . This patient, when 461 examined at the age of 3 years and 10 months, showed 462 generalized hypotonia, failure to thrive, deafness, hepatome-463 galy, psychomotor retardation, absent reflexes, and frequent 464 convulsions. At autopsy, multiple abnormalities were found 465 (Fig. 1) , the only abnormality 505 observed in plasma from patients are elevated VLCFAs (Table   506 2, Fig. 2b ). Studies in fibroblasts have shown that the oxidation 530 Zellweger syndrome indicating that the clinical signs and 531 symptoms of this patient were similar to those described for 532 classical Zellweger syndrome. This patient was originally 533 believed to have peroxisomal 3-ketoacyl-CoA thiolase defi-534 ciency, but upon reinvestigation we found that the true defect in 535 this patient is again at the level of D-bifunctional protein [26] . A 536 number of other patients described in literature with an 537 unknown defect in peroxisomal beta-oxidation, all turned out 538 to suffer from DBP deficiency as well [21] .
539
D-bifunctional protein is a protein with two catalytic 540 activities including a 2-enoyl-CoA hydratase unit and a (3R)-541 hydroxyacyl-CoA dehydrogenase unit. As a consequence three 542 different types of DBP deficiency can be distinguished 543 depending on which activity is deficient: (i) type 1 deficient 544 patients have a deficiency of both the hydratase and 545 dehydrogenase activities of DBP (in fibroblasts of virtually all 546 type 1 deficient patients no DBP protein can be detected by 547 immunoblotting and upon immunofluorescence using an anti-548 body raised against DBP); (ii) type 2 deficient patients, have an 549 isolated deficiency of the hydratase unit; and (iii) type 3 550 deficient patients, have an isolated deficiency of the dehydro-551 genase unit. This classification can be made on the basis of 552 enzyme activity measurements in combination with mutation 553 analysis.
554
Recently, we reported the clinical, biochemical, and genetic 555 characteristics of a large cohort of DBP-deficient patients. 556 Enzyme activity measurements in combination with molecular 557 data revealed that 27% of the patients were DBP type 1 558 deficient, 28% type 2 deficient, and 45% type 3 deficient. No 559 evident differences were found between the clinical signs and 560 symptoms of patients affected by type 1, 2 or 3 deficiency. 561 Virtually all patients presented with neonatal hypotonia (98%), 562 and seizures (93%) within the first months of life. 19 patients 563 (15%) were reported to have had infantile spasms at any time. 564 Failure to thrive was observed in 43% of the patients. Visual 565 system failure, including nistagmus, strabismus or failure to 566 fixate objects at 2 months was reported in 45% of patients. 567 Almost none of the patients acquired any psychomotor 568 development. External dysmorphia was present in 68% of 569 patients and resembled that of patients with Zellweger 570 syndrome. Frequently described abnormalities were: high 571 forehead, high arched palate and large fontanel, long philtrum, 572 epicanthal folds, hypertelorism, microcephaly, shallow supra-573 orbital ridges, retrognatia, and low set ears. Kaplan-Meier 574 survival analysis revealed that all type 1 deficient patients died 575 within the first 14 months of life (mean age of death: 6.9 576 months), whereas the mean age of death for type 2 and type 3 577 deficiency was 10.7 months and 17.6 months. The major cause 578 of death was pneumonia for almost all patients. Only five of the 579 patients showed prolonged survival (> 5 years), one of whom 580 was a type 2 patient and the other 4 type 3 patients. from pristanic acid by beta-oxidation (Fig. 3) . Pristanic acid is a The work was financially supported by grants from the: 
